Disc Medicine, Inc. (NASDAQ:IRON) Receives $104.44 Consensus Price Target from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON) has earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $104.4444.

A number of analysts have recently issued reports on IRON shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush reissued an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Morgan Stanley raised their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 33,000 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $74.96, for a total value of $2,473,680.00. Following the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at approximately $16,945,757.44. This trade represents a 12.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rahul Khara sold 1,649 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $123,675.00. Following the sale, the insider owned 52,173 shares of the company’s stock, valued at approximately $3,912,975. This represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 105,712 shares of company stock worth $7,597,536. 3.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently made changes to their positions in IRON. ANTIPODES PARTNERS Ltd bought a new stake in Disc Medicine during the fourth quarter valued at approximately $33,000. KBC Group NV bought a new position in Disc Medicine in the fourth quarter worth approximately $80,000. Persistent Asset Partners Ltd bought a new position in Disc Medicine in the fourth quarter worth approximately $141,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after acquiring an additional 490 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Disc Medicine by 15,137.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after acquiring an additional 2,422 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Up 2.0%

IRON stock opened at $77.80 on Friday. Disc Medicine has a 1-year low of $40.00 and a 1-year high of $99.50. The business has a fifty day moving average price of $73.12 and a 200-day moving average price of $69.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The stock has a market capitalization of $2.97 billion, a P/E ratio of -11.82 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Equities analysts forecast that Disc Medicine will post -6.62 earnings per share for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.